Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: A review by a Central European Consensus Panel

Guenther G. Steger, Jitka Abrahámová, Florin Bacanu, Stephen Brincat, Arija Brize, Alvydas Česas, Tanja Čufer, Magdolna Dank, Renata Duchnowska, Alexandru Eniu, Jacek Jassem, Zsuzsanna Kahán, Erika Matos, Peeter Padrik, Signe Plāte, Helis Pokker, Gunta Purkalne, Constanta Timcheva, Valentina Tzekova, Rostislav VyzulaChristoph C. Zielinski

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In breast cancer, early detection as well as new developments in therapeutic options has resulted in less patients presenting with metastatic disease. However, about one-third of women with early stage breast cancer will eventually develop metastatic disease. Furthermore, approximately 20-30% of patients with breast cancer have tumors that overexpress human epidermal growth factor receptor (HER-2), which is associated with an aggressive tumor phenotype and poor prognosis. The identification of the HER-2 protein led to the development of highly effective therapeutics directed at this receptor. Trastuzumab, a recombinant, humanized, monoclonal antibody that binds to the extracellular domain of the HER-2 protein, has shown significant clinical benefit in metastatic and early-stage HER-2-positive breast cancer. Since the cancer recurs after adjuvant therapy in some women, and metastatic breast cancer eventually develops resistance to trastuzumab, there is a need for alternative treatment modalities to block HER-2 signaling. One of these treatment options is lapatinib, an orally active small molecule that inhibits the tyrosine kinases of HER-2 and the epidermal growth factor receptor type 1 (EGFR). In this consensus statement current treatment options in metastatic and locally advanced disease are discussed with a special focus on lapatinib.

Original languageEnglish
Pages (from-to)368-379
Number of pages12
JournalWiener Klinische Wochenschrift
Volume122
Issue number11-12
DOIs
Publication statusPublished - Jun 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: A review by a Central European Consensus Panel'. Together they form a unique fingerprint.

  • Cite this

    Steger, G. G., Abrahámová, J., Bacanu, F., Brincat, S., Brize, A., Česas, A., Čufer, T., Dank, M., Duchnowska, R., Eniu, A., Jassem, J., Kahán, Z., Matos, E., Padrik, P., Plāte, S., Pokker, H., Purkalne, G., Timcheva, C., Tzekova, V., ... Zielinski, C. C. (2010). Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: A review by a Central European Consensus Panel. Wiener Klinische Wochenschrift, 122(11-12), 368-379. https://doi.org/10.1007/s00508-010-1373-6